Filing Details
- Accession Number:
- 0001209191-21-056057
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-09-14 19:29:46
- Reporting Period:
- 2021-09-14
- Accepted Time:
- 2021-09-14 19:29:46
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1693415 | Translate Bio Inc. | TBIO | Biological Products, (No Disgnostic Substances) (2836) | 611807780 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1744627 | D. Paul Burgess | C/O Translate Bio, Inc. 29 Hartwell Ave Lexington MA 02421 | Chief Operating Officer, Clo | No | Yes | No | Yes |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2021-09-14 | 71,833 | $38.00 | 0 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2021-09-14 | 219,652 | $0.00 | 219,652 | $7.39 |
| Common Stock | Stock Option (right to buy) | Disposition | 2021-09-14 | 69,953 | $0.00 | 69,953 | $8.34 |
| Common Stock | Stock Option (right to buy) | Disposition | 2021-09-14 | 150,000 | $0.00 | 150,000 | $7.95 |
| Common Stock | Stock Option (right to buy) | Disposition | 2021-09-14 | 150,000 | $0.00 | 150,000 | $7.66 |
| Common Stock | Stock Option (right to buy) | Disposition | 2021-09-14 | 90,000 | $0.00 | 90,000 | $23.82 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2027-12-21 | No | 4 | S | Direct | |
| 0 | 2028-03-06 | No | 4 | S | Direct | |
| 0 | 2029-03-07 | No | 4 | S | Direct | |
| 0 | 2030-03-02 | No | 4 | S | Direct | |
| 0 | 2031-03-08 | No | 4 | S | Direct |
Footnotes
- As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the "Tender Offer"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021.
- Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share.
- This option was granted on December 22, 2017. The shares underlying the option became fully vested on March 9, 2021.
- This option was granted on March 7, 2018. The shares underlying the option are scheduled to vest over four years, with 25% of the shares vesting on March 7, 2019 and the remainder vesting in equal monthly installments through March 7, 2022.
- This option was granted on March 8, 2019. This option will vest as to 25% of the shares on March 8, 2020, and in thirty-six equal monthly installments thereafter as to the remaining shares through March 8, 2023.
- This option was granted on March 3, 2020. This option will vest as to 25% of the shares on December 11, 2020, and in thirty-six equal monthly installments thereafter as to the remaining shares through December 11, 2023.
- This option was granted on March 9, 2021. This option will vest as to 25% of the shares on March 9, 2022, and in thirty-six equal monthly installments thereafter as to the remaining shares though March 9, 2025.
Billionaire Hedge Funds
